2024
219 CFTR dysfunction shapes airway immune cell compositions contributing to lung pathogenesis in children with cystic fibrosis
Kizilirmak T, Yin H, Garrison A, Browne J, Bruscia E, Egan M, Britto C. 219 CFTR dysfunction shapes airway immune cell compositions contributing to lung pathogenesis in children with cystic fibrosis. Journal Of Cystic Fibrosis 2024, 23: s119. DOI: 10.1016/s1569-1993(24)01059-2.Peer-Reviewed Original Research
2022
Update on Innate and Adaptive Immunity in Cystic Fibrosis
Bruscia E, Bonfield T. Update on Innate and Adaptive Immunity in Cystic Fibrosis. Clinics In Chest Medicine 2022, 43: 603-615. PMID: 36344069, DOI: 10.1016/j.ccm.2022.06.004.Peer-Reviewed Original ResearchConceptsChronic infectionCFTR modulator therapyRobust inflammatory responseCystic fibrosis pathophysiologyImmune dysregulationPatient ageExcessive inflammationModulator therapyLung microenvironmentLung infectionImmune mechanismsInflammatory responseAdaptive immunityMucociliary transportCF life expectancyCF lungCystic fibrosisInfectionLife expectancyImmunityCritical roleCurrent understandingMorbidityInflammationFibrosis
2002
Towards the pharmacogenomics of cystic fibrosis
Sangiuolo F, DApice M, Bruscia E, Lucidi V, Novelli G. Towards the pharmacogenomics of cystic fibrosis. Pharmacogenomics 2002, 3: 75-87. PMID: 11966405, DOI: 10.1517/14622416.3.1.75.Peer-Reviewed Original ResearchConceptsCystic fibrosisPancreatic insufficiencyChronic obstructive lung diseaseRelated clinical diseasesObstructive lung diseaseElevated sweat chloride concentrationsExocrine pancreatic insufficiencySweat chloride concentrationCongenital bilateral absenceMultiorgan diseaseChronic pancreatitisClinical symptomsLung diseaseDrug therapyClinical diseaseClinical overlapRecessive genetic diseaseTherapeutic questionsBilateral absenceDrug efficacyDiseaseVas deferensTherapy approachesFibrosisSymptoms